---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-009820"
form_type: "8-K"
ticker: "ERAS"
cik: "0001761918"
company_name: "Erasca, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:54:50.074196+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Erasca reports early PRs for ERAS-0015 at 8 mg QD; Phase 1 dose escalation faster than expected

## Summary
- ERAS-0015 AURORAS-1 trial: two confirmed PRs and one unconfirmed PR in patients with different tumor types and RAS mutations at 8 mg QD.
- No dose-limiting toxicities; predominantly low-grade AEs; linear PK across all dose levels evaluated (data cutoff Jan 7, 2026).
- Initial Phase 1 monotherapy data for ERAS-0015 planned for H1 2026; expansion/combination cohorts start H2 2026.
- ERAS-4001 BOREALIS-1 Phase 1 dose escalation advancing as expected; initial monotherapy data planned H2 2026.

## SEC filing metadata
- accession: 0001193125-26-009820
- form_type: 8-K
- ticker: ERAS
- cik: 0001761918
- company_name: Erasca, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761918/000119312526009820/0001193125-26-009820-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761918/000119312526009820/eras-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-009820
- JSON: https://secwatch.observer/filing/0001193125-26-009820.json
- Plain text: https://secwatch.observer/filing/0001193125-26-009820.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.